期刊文献+
任意字段
题名或关键词
题名
关键词
文摘
作者
第一作者
机构
刊名
分类号
参考文献
作者简介
基金资助
栏目信息

Do we need a new levodopa?

Do we need a new levodopa?
下载PDF
导出
摘要 Idiopathic Parkinson＇s disease（PD）is classified as a chronic progressive neurodegenerative disease.Various each other complementing,still hypothetical aetiologies describe the predominant dopaminergic neuronal death.They include genetic predisposition,exogenous environmental or endogenous toxin exposure,impaired detoxification. Idiopathic Parkinson＇s disease（PD）is classified as a chronic progressive neurodegenerative disease.Various each other complementing,still hypothetical aetiologies describe the predominant dopaminergic neuronal death.They include genetic predisposition,exogenous environmental or endogenous toxin exposure,impaired detoxification.
作者 Thomas Müller
机构地区 Department of Neurology
出处 《Neural Regeneration Research》 SCIE CAS CSCD 2016年第5期731-732,共2页 中国神经再生研究（英文版）
关键词 RGMa COMT Do we need a new levodopa PLP GSH
分类号 R742.5 [医药卫生—神经病学与精神病学]
  • 相关文献

参考文献10

  • 1Fahn S (2006) Levodopa in the treatment of Parkinson's disease, l Neural Transm Suppl 1-15.
  • 2Hinz M, Stein A, Cole T (2014) The Parkinson's disease death rate: carbidopa and vita- min B6. Clin Pharmacol 6:161-169.
  • 3Mfi.ller T (2013) Detoxification and antioxidative therapy for levodopa-induced neuro degeneration in Parkinson's disease. Expert Rev Neurother 13:707-718.
  • 4MOiler T, Kuhn W (2009) Cysteine elevation in levodopa-treated patients with Parkin- son's disease. Mov Disord 24:929-932.
  • 5M~ller T, Muhlack S (2014) Levodopa-related cysteinyl-glycine and cysteine reduction with and without catechol-O-methyltransferase inhibition in Parkinson's diseasc pa- tients. J Neural Transm 121:643 648.
  • 6Mtiller T, Kohlhepp W 12016) Hypomethylation in Parkinson's disease: An epigenetic drug effect? Mov Disord doi: 10. 1002/mds.26560.
  • 7MOiler T, Trommer I, Muhlack S, Mueller BK (2016) Levodopa increases oxidative stress and repulsive guidance molecule A levels: a pilot study in patients with Parkinson's disease. J Neural Transm 123:41/l-406.
  • 8Przuntek H, MO.11er T, Riederer P (2004) Diagnostic staging of Parkinson's disease: con- ceptual aspects. J Neural Transm 111:20 l-216.
  • 9Schapira AH, McDermott MP, Barone P, Cornelia CL, Albrecht S, Hsu HH, Massey DH, Mizuno Y, Poewe W, Rascol O, Marek K (2013) Pramipexole in patients with early Parkinson's disease (PROUD): a randomised delayed-start trial. Lancet Neurol 12:747-755.
  • 10Taravini IR, Larramendy C, Gomez G, Saborido MD, Spaans F, Fresno C, Gonzalez GA, Fernandez E, Murer MG, Gershanik OS (2016) Contrasting gene expression patterns induced by levodopa and pramipexole treatments in the rat model of Parkinsun's disease. Neuropharmacology 101:576 589.
Neural Regeneration Research
2016年 第5期

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部